Eli Lilly and Company $LLY Shares Purchased by ABN Amro Investment Solutions

ABN Amro Investment Solutions grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 69.5% in the fourth quarter, HoldingsChannel.com reports. The fund owned 137,274 shares of the company’s stock after acquiring an additional 56,281 shares during the quarter. Eli Lilly and Company accounts for 2.2% of ABN Amro Investment Solutions’ holdings, making the stock its 7th biggest position. ABN Amro Investment Solutions’ holdings in Eli Lilly and Company were worth $147,526,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Maryland Capital Advisors Inc. acquired a new stake in Eli Lilly and Company during the 4th quarter worth about $25,000. Miller Global Investments LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter worth about $33,000. E Fund Management Hong Kong Co. Ltd. boosted its position in shares of Eli Lilly and Company by 342.9% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after purchasing an additional 24 shares in the last quarter. Dorato Capital Management bought a new position in shares of Eli Lilly and Company during the 4th quarter worth about $36,000. Finally, New England Capital Financial Advisors LLC boosted its position in shares of Eli Lilly and Company by 142.9% during the 4th quarter. New England Capital Financial Advisors LLC now owns 34 shares of the company’s stock worth $37,000 after purchasing an additional 20 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 0.5%

NYSE:LLY opened at $1,016.05 on Thursday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The firm has a market cap of $956.85 billion, a price-to-earnings ratio of 36.09, a price-to-earnings-growth ratio of 1.11 and a beta of 0.48. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The firm has a 50-day moving average price of $940.69 and a two-hundred day moving average price of $1,002.07.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter last year, the business posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 35.82 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on LLY shares. BMO Capital Markets reissued an “outperform” rating and set a $1,300.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Cantor Fitzgerald increased their price objective on shares of Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an “overweight” rating in a research report on Friday, May 1st. Daiwa Securities Group increased their price objective on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Wolfe Research reissued an “outperform” rating and set a $1,325.00 price objective on shares of Eli Lilly and Company in a research report on Monday, May 4th. Finally, Truist Financial reissued a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $1,218.33.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly said results from its oral GLP-1 program are encouraging, supporting the outlook for a future pill that could broaden the company’s obesity and diabetes franchise. From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
• Positive Sentiment: The company expanded its pipeline with the acquisition of Engage Biologics for up to $202 million, adding non-viral DNA delivery technology and strengthening its genetic medicine ambitions. Eli Lilly Buys Engage Biologics for Up to $202 Million
• Positive Sentiment: Lilly also expanded access to its TuneLab AI/ML drug discovery platform through a partnership with Collaborative Drug Discovery, reinforcing its push to use artificial intelligence to accelerate R&D. Collaborative Drug Discovery Partners with Lilly TuneLab to Make Lilly AI/ML Models Available in CDD Vault
• Positive Sentiment: Analysts and industry coverage highlighted Lilly’s strong earnings call and its high R&D performance, which support the view that the company’s growth trajectory remains strong. Eli Lilly Earnings Call Signals High-Growth Trajectory
• Neutral Sentiment: Lilly completed a large $8.9 billion debt offering, which gives the company additional financial flexibility but also increases leverage. Eli Lilly Raises $8.9 Billion in Debt Offering
• Neutral Sentiment: A lawsuit alleging more than $200 million in Trulicity rebate fraud is a separate risk factor, though it appears to be more about recovering losses than a direct operational setback. Eli Lilly accuses church bishops, businessmen of fraud in Trulicity drug rebate scheme

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.